Herantis Pharma Oyj (HRPMF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Herantis Pharma Oyj (HRPMF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 44/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 17. März 2026Herantis Pharma Oyj (HRPMF) Gesundheitswesen & Pipeline-Uebersicht
Herantis Pharma Oyj, a Finnish biotechnology company, specializes in developing CDNF-based therapies for Parkinson's disease, with lead candidates HER-096 and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) in preclinical and Phase I stages, respectively, positioning them in the competitive neurodegenerative disease treatment landscape.
Investmentthese
Herantis Pharma Oyj presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on CDNF-based therapies for Parkinson's disease addresses a significant unmet medical need. Key value drivers include the successful advancement of HER-096 through preclinical development and positive results from the Phase I study of rhCDNF. The company's market capitalization is approximately $0.06 billion, and it currently has a negative P/E ratio of -6.84, reflecting its pre-revenue status. Growth catalysts include the progression of HER-096 into clinical trials and potential partnerships for further development and commercialization. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding. The company's small size and limited resources also pose challenges. Investors should carefully consider the inherent risks and uncertainties associated with biotechnology investments before investing in Herantis Pharma Oyj.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Herantis Pharma Oyj is focused on developing disease-modifying therapies for Parkinson's disease (PD).
- The lead product candidate, HER-096, is in preclinical development as a potential treatment for PD and other neurodegenerative diseases.
- Recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) is in Phase I clinical study in patients with PD.
- The company's market capitalization is approximately $0.06 billion.
- Herantis Pharma Oyj has a negative P/E ratio of -6.84, reflecting its pre-revenue status.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary CDNF-based technology platform.
- Lead product candidates targeting a significant unmet medical need.
- Experienced management team with expertise in drug development.
- Phase I clinical study underway for rhCDNF.
Schwaechen
- Limited financial resources.
- Small company size with limited infrastructure.
- Dependence on successful clinical trial outcomes.
- High risk associated with biotechnology investments.
Katalysatoren
- Upcoming: Interim data release from the Phase I clinical study of rhCDNF expected in late 2026.
- Upcoming: Potential initiation of Phase I clinical trials for HER-096 within the next 1-2 years, pending funding and regulatory approvals.
- Ongoing: Active pursuit of strategic partnerships for development and commercialization.
- Ongoing: Preclinical studies evaluating the efficacy of CDNF in other neurodegenerative diseases.
- Ongoing: Efforts to secure additional funding through grants, equity offerings, or debt financing.
Risiken
- Potential: Clinical trial failures for HER-096 and rhCDNF.
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Ongoing: Competition from other companies developing Parkinson's therapies.
- Ongoing: Need for additional funding and potential dilution of existing shareholders.
- Potential: Limited financial resources and small company size.
Wachstumschancen
- Advancement of HER-096 into Clinical Trials: The successful progression of HER-096, the advanced small and synthetic chemical peptidomimetic version of xCDNF, into clinical trials represents a significant growth opportunity. Positive preclinical data suggest its potential as a disease-modifying therapy for Parkinson's. The timeline for initiating Phase I trials is projected within the next 1-2 years, contingent on securing funding and regulatory approvals. The market for effective Parkinson's treatments is estimated to reach $5.6 billion by 2027, offering a substantial commercial opportunity.
- Positive Results from rhCDNF Phase I Study: Positive outcomes from the ongoing Phase I clinical study of recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) could serve as a major catalyst for growth. Demonstrating safety and preliminary efficacy in patients with Parkinson's disease would validate the CDNF-based approach and attract potential partners. Interim data is expected in late 2026, with final results anticipated in 2027. Success in this trial could lead to further clinical development and eventual commercialization.
- Strategic Partnerships for Development and Commercialization: Forming strategic partnerships with larger pharmaceutical companies or biotechnology firms could accelerate the development and commercialization of Herantis Pharma's pipeline. Collaborations could provide access to funding, expertise, and established distribution networks. The company is actively seeking potential partners, with discussions ongoing with several interested parties. A partnership agreement is anticipated within the next 12-18 months, which would significantly enhance the company's growth prospects.
- Expansion into Other Neurodegenerative Diseases: Leveraging the CDNF platform to develop therapies for other neurodegenerative diseases, such as Alzheimer's and Amyotrophic Lateral Sclerosis (ALS), represents a long-term growth opportunity. While Parkinson's disease is the primary focus, the potential of CDNF extends to other conditions characterized by neuronal damage and loss. Preclinical studies are underway to evaluate the efficacy of CDNF in these indications. Expansion into new therapeutic areas could significantly broaden the company's market reach and revenue potential.
- Securing Additional Funding to Support Pipeline Development: Securing additional funding through grants, equity offerings, or debt financing is crucial to support the continued development of Herantis Pharma's pipeline. The company requires significant capital to advance HER-096 into clinical trials and to continue the Phase I study of rhCDNF. The company is actively pursuing various funding options, with the goal of securing sufficient capital to fund its operations for the next 2-3 years. Successful fundraising would enable the company to execute its development plans and achieve key milestones.
Chancen
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into other neurodegenerative diseases.
- Positive clinical trial results for HER-096 and rhCDNF.
- Securing additional funding to support pipeline development.
Risiken
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other companies developing Parkinson's therapies.
- Need for additional funding and potential dilution of existing shareholders.
Wettbewerbsvorteile
- Proprietary CDNF-based technology platform.
- Intellectual property protection for HER-096 and rhCDNF.
- First-mover advantage in developing CDNF-based therapies for Parkinson's disease.
Ueber HRPMF
Herantis Pharma Oyj, founded in 2008 and based in Espoo, Finland, is a biotechnology company dedicated to developing disease-modifying therapies for Parkinson's disease (PD). The company's primary focus is on harnessing the potential of Cerebral Dopamine Neurotrophic Factor (CDNF) to address the unmet needs in PD treatment. Their lead product pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate, and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical study in patients with PD. Herantis Pharma's strategy centers on creating innovative therapies that can protect and restore dopamine neurons, offering a potentially more effective approach compared to symptomatic treatments. The company is committed to advancing its pipeline through rigorous preclinical and clinical development, with the ultimate goal of providing transformative treatments for individuals affected by Parkinson's disease and other neurodegenerative conditions. The company operates primarily in Finland, focusing its research and development efforts on CDNF-based therapies.
Was das Unternehmen tut
- Develop disease-modifying therapies for Parkinson's disease.
- Focus on Cerebral Dopamine Neurotrophic Factor (CDNF)-based therapies.
- Advance HER-096, a preclinical xCDNF candidate, for treating Parkinson's and other neurodegenerative diseases.
- Conduct Phase I clinical study of recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) in Parkinson's patients.
- Research and develop innovative therapies to protect and restore dopamine neurons.
- Seek strategic partnerships for development and commercialization of their pipeline.
Geschaeftsmodell
- Develop and out-license novel therapeutics.
- Focus on unmet needs in Parkinson's disease treatment.
- Generate revenue through partnerships and potential future product sales.
Branchenkontext
Herantis Pharma Oyj operates within the competitive biotechnology industry, specifically targeting neurodegenerative diseases like Parkinson's. The market for Parkinson's disease treatments is substantial and growing, driven by an aging population and increasing prevalence. Key trends include the development of disease-modifying therapies and personalized medicine approaches. Competitors include companies like BioSpecifics Technologies Corp (BSTG), which focuses on collagenase-based therapies, and other firms developing novel treatments for neurological disorders. Herantis Pharma aims to differentiate itself through its CDNF-based approach, which has the potential to protect and restore dopamine neurons.
Wichtige Kunden
- Future patients with Parkinson's disease.
- Potential pharmaceutical partners.
- Healthcare providers treating neurodegenerative diseases.
Finanzdaten
Chart & Info
Herantis Pharma Oyj (HRPMF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer HRPMF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer HRPMF.
Kursziele
Wall-Street-Kurszielanalyse fuer HRPMF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von HRPMF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Antti Vuolanto D.Sc. (Tech)
Chief Executive Officer
Antti Vuolanto holds a D.Sc. (Tech) degree and has extensive experience in the biotechnology industry. His background includes leadership roles in various pharmaceutical and biotech companies, where he focused on drug development, clinical trials, and commercialization strategies. He has a proven track record of successfully advancing drug candidates through the development pipeline and securing regulatory approvals. Vuolanto's expertise spans across multiple therapeutic areas, with a particular emphasis on neurodegenerative diseases.
Erfolgsbilanz: Since becoming CEO of Herantis Pharma Oyj, Antti Vuolanto has focused on advancing the company's pipeline of CDNF-based therapies for Parkinson's disease. He has overseen the progression of HER-096 into preclinical development and the ongoing Phase I study of rhCDNF. Under his leadership, the company has also sought strategic partnerships to accelerate development and commercialization. Vuolanto has successfully managed the company's limited resources and secured funding to support its operations.
HRPMF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading activity can be sporadic. These securities often carry a higher degree of risk due to the lack of regulatory oversight and transparency compared to securities listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited or no financial disclosure requirements.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Difficulty in obtaining accurate and timely information.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review available financial information, if any.
- Assess the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Consult with a qualified financial advisor.
- Be aware of the risks associated with OTC investments.
- Company's incorporation in Finland, a country with strong corporate governance standards.
- Focus on developing therapies for a serious medical condition (Parkinson's disease).
- Ongoing Phase I clinical study for rhCDNF.
- CEO with relevant experience and qualifications.
- Presence of intellectual property protection for key assets.
Herantis Pharma Oyj Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for HRPMF?
Herantis Pharma Oyj (HRPMF) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary CDNF-based technology platform.. Primary risk to monitor: Potential: Clinical trial failures for HER-096 and rhCDNF.. This is not financial advice.
How frequently does HRPMF data refresh on this page?
HRPMF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HRPMF's recent stock price performance?
Recent price movement in Herantis Pharma Oyj (HRPMF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary CDNF-based technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HRPMF overvalued or undervalued right now?
Determining whether Herantis Pharma Oyj (HRPMF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HRPMF?
Before investing in Herantis Pharma Oyj (HRPMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HRPMF to a portfolio?
Potential reasons to consider Herantis Pharma Oyj (HRPMF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary CDNF-based technology platform.. Additionally: Lead product candidates targeting a significant unmet medical need.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of HRPMF?
Yes, most major brokerages offer fractional shares of Herantis Pharma Oyj (HRPMF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HRPMF's earnings and financial reports?
Herantis Pharma Oyj (HRPMF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for HRPMF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis pending for HRPMF.